We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

DIASORIN MOLECULAR

DiaSorin Molecular LLC manufactures and distributes innovative molecular diagnostic products on the versatile LIAISON... read more Featured Products: More products

Download Mobile App




Blood Culture Assay Enhances Diagnostic Stewardship Through Targeted Panel Selection

By LabMedica International staff writers
Posted on 10 Jun 2025

Each year, around 250,000 individuals in the US are diagnosed with bloodstream infections (BSIs). More...

Sepsis caused by these infections carries a mortality rate ranging from 16% to 40%, and any delay in administering appropriate treatment further heightens patient risk. Sepsis is also the most costly reason for hospitalization in the US, with expenses exceeding USD 20 billion annually. When a bloodstream infection is suspected, laboratories begin by performing cultures and Gram staining. Based on the Gram stain findings, which identify the pathogen type, such as yeasts, gram-positive, or gram-negative bacteria, the lab can then select the most suitable molecular test panel. This targeted testing method helps reduce overall costs compared to broader approaches that test for a wide array of pathogens regardless of Gram stain results. Now, a new assay designed specifically for gram-positive pathogens offers clinicians the ability to improve diagnostic stewardship by enabling more precise and cost-effective panel selection.

Diasorin’s (Saluggia VC, Italy) LIAISON PLEX® Gram-Positive Blood Culture Assay detects 17 targets (13 gram-positive bacteria and 4 relevant resistance gene targets) in under 2 hours, including Bacillus spp. and mecC, in addition to the targets currently found on the VERIGENE® Gram-Positive Blood Culture Test, providing clinicians with the ability to make rapid and targeted treatment decisions. The assay features Diasorin’s proprietary NanoGrid technology, which allows the detection of nucleic acids without the need for conventional amplification reactions, thereby minimizing the risk of false positives.

Diasorin has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LIAISON PLEX® Gram-Positive Blood Culture Assay, the final syndromic blood culture panel for the microbiological diagnosis of bloodstream infections on the LIAISON PLEX®. Diasorin has now received 510(k) clearance from the FDA for both the respiratory and the blood culture portfolio on the LIAISON PLEX®.

“With this FDA clearance, we are now positioned to offer our expanding customer base a comprehensive and flexible menu of multiplex panels for the diagnosis of bloodstream infections on the LIAISON PLEX®,” said Angelo Rago, President of Luminex. “This milestone provides clinicians with unmatched flexibility to tailor blood culture panels based on individual patient needs. We are committed to continue expanding our offering on the platform to ensure broad access to our multiplexing solutions that deliver fast, accurate, and cost-effective results, ultimately supporting improved patient outcomes.”


New
Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.